Home Uncategorized Page 8

Uncategorized

Latest

William Leonard Pickard interviews Bryan Hubbard about the new policy frontier of Ibogaine

Psychedelic legend “the Acid King” William Leonard Pickard Announced as Keynote Speaker at the 2025 North Florida Entheogenic Conference

atai Life Sciences Announces the Publication of Beckley Psytech’s Phase 1 Study of BPL-003 in the Journal of Psychopharmacology

atai Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate and Clinical Highlights

atai Impact Establishes the atai Fellowship Fund in Psychedelic Neuroscience with...

Apeiron and Other Key Shareholders of atai Life Sciences Reinforce Support...

atai Life Sciences Announces Successful Outcome of Phase 2a Biomarker Trial...

atai Life Sciences Has Been Selected for Addition to the NASDAQ...

atai Life Sciences launches TryptageniX to further expand atai’s robust intellectual...

atai Life Sciences Increases its Ownership Position in COMPASS Pathways

atai Life Sciences Reports Third Quarter 2021 Financial Results and Corporate...

atai Life Sciences to Host Conference Call and Webcast to Discuss...

Video Briefing: The Psychedelics Executive Order

President Trump Signs Executive Order to Accelerate Psychedelic Research and Access

Op-Ed: Iboga, Ibogaine & 5-MeO-DMT: What gets missed when complex medicines...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.